Wolwo Bio-Pharmaceutical (300357.SZ) Forecasts H1 2025 Profit Growth; Net Attributable Income Expected at 170-185 Million Yuan, Up 13.92%-23.97% YoY

Stock Track07-15

Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170 million yuan and 185 million yuan, reflecting a robust year-on-year surge of 13.92% to 23.97%. Furthermore, net profit after excluding non-recurring items is anticipated to climb to 166 million yuan to 181 million yuan, marking a substantial increase of 16.96% to 27.56% compared with the prior-year period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197215258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197215258","market":"us","top_or_hot":-1,"title":"Wolwo Bio-Pharmaceutical (300357.SZ) Forecasts H1 2025 Profit Growth; Net Attributable Income Expected at 170-185 Million Yuan, Up 13.92%-23.97% YoY","media":"Stock Track","content":"<p>Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170 million yuan and 185 million yuan, reflecting a robust year-on-year surge of 13.92% to 23.97%. Furthermore, net profit after excluding non-recurring items is anticipated to climb to 166 million yuan to 181 million yuan, marking a substantial increase of 16.96% to 27.56% compared with the prior-year period.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wolwo Bio-Pharmaceutical (300357.SZ) Forecasts H1 2025 Profit Growth; Net Attributable Income Expected at 170-185 Million Yuan, Up 13.92%-23.97% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWolwo Bio-Pharmaceutical (300357.SZ) Forecasts H1 2025 Profit Growth; Net Attributable Income Expected at 170-185 Million Yuan, Up 13.92%-23.97% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 20:08 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170 ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1197215258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197215258","pubTimestamp":1752581335,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":null,"summary":"Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"300357":"我武生物","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"沃尔沃生物制药（300357.SZ）预测2025年上半年利润增长；预计归属净利润1.7亿-1.85亿元，同比增长13.92%-23.97%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300357":1},"content_text":"Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170 million yuan and 185 million yuan, reflecting a robust year-on-year surge of 13.92% to 23.97%. Furthermore, net profit after excluding non-recurring items is anticipated to climb to 166 million yuan to 181 million yuan, marking a substantial increase of 16.96% to 27.56% compared with the prior-year period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197215258","isCrawlerRequest":true}